News

Halozyme has posted a net loss of $11.8m for the first quarter 2010, or $ 0.13 per diluted share, compared to $14.7m, or $ 0.18 per diluted share,

For the first quarter of 2010, Watson Pharmaceuticals posted a net income of $69.8m, or $0.57 per diluted share, compared to $49.1m, or $0.43 per diluted share, for

GenScript said that antibody drug is among the powerful forms of medication. There are research and development activities to develop antibody drugs for numerous serious diseases, such as

NVA237 was licensed to Novartis by Sosei and its co-development partner Vectura Group in a 2005 deal in which the two companies could receive up to $375m in

Valeant Onsolis is an opioid analgesic indicated only for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and

Osiris Therapeutics has posted a net income of $2.4m for the first quarter of 2010, or $0.07 per diluted share, compared to $14.7m, or $0.45 per diluted share,

IntelliCyt said that the new HTFC Screening System, designed to enable large scale, high throughput, high content screening, takes a new approach to cell-based screening by integrating the

BioGaia said that apart from positive results on gastrointestinal symptoms and hospital stay, supplementation of L reuteri protectis also led to a reduction in number of days of

Generex is expected to continue to monitor and execute the ongoing Generex Oral-lyn study according to protocol and national/international ICH-GCPs. The study’s endpoint is for Generex Oral-lyn to